Core Viewpoint - The company reported significant financial growth for the year ending December 31, 2025, achieving a total revenue of 13.042 billion yuan, a year-on-year increase of 38.4% [1] Financial Performance - Total revenue reached 13.042 billion yuan, up 38.4% year-on-year - Gross profit was 11.286 billion yuan, reflecting a 42.6% increase - The company achieved its first annual profit with an IFRS net profit of 814 million yuan, a turnaround from a loss of 94.63 million yuan in 2024 [1] - Product revenue amounted to 11.896 billion yuan, a 44.6% increase, driven by a strong position in the oncology sector and rapid expansion of the product line - Licensing revenue decreased to 957 million yuan from 1.1 billion yuan in 2024, but overall revenue growth supported improved profitability - Non-IFRS net profit surged to 1.723 billion yuan, a remarkable increase of 419.6% [1] Strategic Initiatives - The company implemented a "dual-drive" strategic upgrade in 2025, with both oncology and comprehensive product lines contributing to business growth - Three core innovative assets have entered or are about to enter global Phase III clinical trials, laying a foundation for future growth - The product portfolio has expanded to 18 marketed products, with 12 included in the National Reimbursement Drug List (NRDL) in China, further solidifying market position [1]